Deletion of Foxp3+ regulatory T cells in genetically targeted mice supports development of intestinal inflammation
© Boehm et al.; licensee BioMed Central Ltd. 2012
Received: 3 September 2010
Accepted: 11 July 2012
Published: 31 July 2012
Mice lacking Foxp3+ regulatory T (Treg) cells develop severe tissue inflammation in lung, skin, and liver with premature death, whereas the intestine remains uninflamed. This study aims to demonstrate the importance of Foxp3+ Treg for the activation of T cells and the development of intestinal inflammation.
Foxp3-GFP-DTR (human diphtheria toxin receptor) C57BL/6 mice allow elimination of Foxp3+ Treg by treatment with Dx (diphtheria toxin). The influence of Foxp3+ Treg on intestinal inflammation was tested using the CD4+ T-cell transfer colitis model in Rag−/− C57BL/6 mice and the acute DSS-colitis model.
Continuous depletion of Foxp3+ Treg in Foxp3-GFP-DTR mice led to dramatic weight loss and death of mice by day 28. After 10 days of depletion of Foxp3+ Treg, isolated CD4+ T-cells were activated and produced extensive amounts of IFN-γ, IL-13, and IL-17A. Transfer of total CD4+ T-cells isolated from Foxp3-GFP-DTR mice did not result in any changes of intestinal homeostasis in Rag−/− C57BL/6 mice. However, administration of DTx between days 14 and 18 after T-cell reconstitution, lead to elimination of Foxp3+ Treg and to immediate weight loss due to intestinal inflammation. This pro-inflammatory effect of Foxp3+ Treg depletion consecutively increased inflammatory cytokine production. Further, the depletion of Foxp3+ Treg from Foxp3-GFP-DTR mice increased the severity of acute dSS-colitis accompanied by 80% lethality of Treg-depleted mice. CD4+ effector T-cells from Foxp3+ Treg-depleted mice produced significantly more pro-inflammatory cytokines.
Intermittent depletion of Foxp3+ Treg aggravates intestinal inflammatory responses demonstrating the importance of Foxp3+ Treg for the balance at the mucosal surface of the intestine.
Immunological tolerance and prevention of autoimmunity is mediated by two categories of mechanisms – recessive and dominant . Recessive tolerance is based on cell-intrinsic mechanisms that include elimination of self-reactive thymocytes or chronically stimulated peripheral T cell clones by apoptosis or their inactivation resulting from anergy induction. dominant tolerance leading to the prevention of autoimmune responses is mediated by a specialized subset of immune cells acting to restrain pathogenic immune responses. Regulatory T cells expressing the forkhead family transcription factor Foxp3 play a nonredundant role in maintaining dominant immunological tolerance. The transcription factor Foxp3 is specifically expressed in regulatory T cells (Treg) and is required for their development [2–6]. Loss-of-function mutations in the gene encoding Foxp3 in mice and humans result in a lack of Treg and in fatal autoimmune pathology beginning at a very early age and affecting multiple organs . The identification of mutations in the gene encoding Foxp3 as the cause of aggressive autoimmunity in human patients with IPEX syndrome (immunodysregulation, polyendocrinopathy, enteropathy, X-linked syndrome) and in the mutant mouse strain scurfy and the subsequent discovery of the essential function of Foxp3 in the development of Treg have provided a genetic foundation for the phenomenon of Treg-mediated dominant tolerance [8, 9]. Although several lymphoid cell subsets exhibit suppressive or immunomodulatory properties, Foxp3-expressing Treg represent the only currently known population of lymphocytes acting as dedicated mediators of dominant tolerance, whose suppressor function is vital for the maintenance of immune homeostasis. Treg cells suppress immune responses through a variety of mechanisms including the production of anti-inflammatory cytokines, direct cell-cell contact, and by modulating the activation state and function of antigen-presenting cells .
The immune response in the intestine is a tightly controlled balance between innate and adaptive effector responses and negative regulatory pathways of control [11–14]. Disruption of this balance by genetic or environmental factors can lead to chronic inflammatory syndromes such as the inflammatory bowel diseases (IBDs). Foxp3+ Treg play a nonredundant role in immune homeostasis, preventing pathological inflammatory responses to environmental and self-antigens . Mouse models of intestinal inflammation have also pinpointed a key role for Treg cells in intestinal homeostasis, as illustrated in a model of T cell–driven colitis induced by the transfer of naive CD4+ T cells into RAG−/− mice [12–14]. Disease development can be prevented and cured by transfer of CD4+CD25+ Treg cells, providing a tractable model to unravel factors controlling the accumulation and function of colitogenic T cells and Treg cells in vivo .
However, the importance of intrinsic Treg, which are constantly mediating the balance of the homeostasis at the mucosal barrier in the colon, for the development of acute and chronic intestinal inflammation is accepted, yet mechanistically rather unclear. In this manuscript we present data on the effects of Foxp3+ Treg deletion on the development of intestinal inflammation in genetically targeted mice. Intermittent deletion of Foxp3+ Treg resulted in a general activation of effector T cells without differentiation in a particular T helper cell subset. Further, deletion of Foxp3+ Treg built the basis for the development of severe acute DSS-colitis and chronic T cell-mediated intestinal inflammation.
Specific pathogen-free Foxp3-GFP-DTR (C57BL/6) mice were provided by A. Rudensky (Washington University/Sloan-Kettering Institute). Foxp3-GFP mice were kindly provided by M. Oukka (Washington University). Rag1−/− mice were obtained from Jackson Laboratories (Bar Harbor, ME). Foxp3-GFP-DTR and Foxp3-GFP mice were housed in the animal facility at the University of Regensburg. Animal use was approved by the ethics committee and adhered to the Laboratory Animal Care Guidelines of the University of Regensburg.
Induction of colitis and deletion of Foxp3+ Treg
Acute DSS-colitis was induced by 5% DSS in drinking water for 5 days followed by normal drinking water for 2 days. Transfer colitis was induced by intravenous injection of CD4+CD62L+CD25- cells (2.5 × 10  cells/mouse) obtained from Foxp3-GFP-DTR mice or Foxp3-GFP mice into Rag1−/− mice. deletion of Foxp3+ Treg was performed by IP administration of 10 μgdTx per kg body weight.
Cell isolation and cytokine measurement
CD4+ cells from spleen and mesenteric lymph nodes were isolated by magnetic bead sorting (Miltenyi Biotec, Bergisch Gladbach, Germany) and cultured 48h under stimulation with plate-bound anti-CD3 antibody (10μg/ml) and soluble anti-CD28 antibody (1μg/ml) (BD Biosciences, San Jose, California, USA. Cytokine concentrations were measured by ELISA according to manufacturer’s instructions. ELISA kits were purchased from BD Biosciences (San Jose, California, USA).
Formalin-fixed and paraffin-embedded samples were deparaffined, rehydrated, and pretreated with 3% hydrogenperoxide in PBS buffer. Sections were incubated with anti-Ki-67 antibody (Roche, Mannheim, Germany) for 1h at room temperature. After incubation with biotin-conjugated secondary antibody and streptavidin-HRP, positive signals were visualized by DAB kit (BD pharmingen, San Jose, California, USA). Paraffin-embedded colon sections were also cut and then stained with H&E. For calculation of inflammation indices in treated and control group of mice, the H&E sections were read by investigators blinded to the experimental protocol and evaluated according to formerly published scoring systems for colitis .
Mesenteric lymph node cells were isolated and subjected to flow cytometry. For staining, cells were treated with monoclonal antibodies to mouse anti-CD3 and anti-CD4 antibody (all from eBiosciences, San Diego, California, USA), respectively. Foxp3 was detected by the genetically determined green fluorescent protein. Nonspecific binding of antibodies was blocked by preincubation with Fcγ-block. Cells were pretreated with BD Cytofix/Cytoperm (BD pharmingen, San Jose, California, USA).
Before statistical analysis normal distribution was tested with Kolmogorov-Smirnow-Lilliefors test with p ≤ 0.05 considered as normally distributed. Normal distributed data was evaluated with standard two-tailed Student´s t-tests with p-values p ≤ 0.05 considered marginally significant. For data not showing a normal distribution we used Wilcoxon-Mann–Whitney tests for statistical analysis. For comparison of survival rates the log rank test was used. Significant data sets are labelled with an asterisk (*). We evaluated the statistics with SPSS Statistics software (SPSS GmbH Software, Munich, Germany). Graph Pad Prism was used to calculate the Standard deviation (SD) between experimental data sets containing equal number of replicates. In the case of different numbers of replicates the Standard Error of the Mean (SEM) was used.
For the experiments presented in this manuscript we used Foxp3-GFP-DTR mice on a C57BL/6 background [2, 3]. The genome of these mice carries a knock-in cDNA sequence encoding the human diphtheria toxin receptor (DTR) fused to sequences encoding green fluorescent protein (GFP) and linked with an internal ribosome entry site (IRES). This sequence is incorporated into the 3’ untranslated region of Foxp3 to produce Foxp3DTR. In these mice GFP and DTR are only detected in Foxp3+ Treg, not in Foxp3- effector T cells. To specifically eliminate Foxp3+ Tregdiphtheria toxin (DTx) needs to be administrated IP to the mice. As previously shown and also corroborated in preparation for this set of experiments, a single injection of DTx induced a transient deletion of Foxp3+ Treg for approximately 48 h with an almost 50% recovery being achieved 72 h after DTx administration (Additional file 1: Figure S1). To identify the dose of diphtheria toxin that induced Foxp3+ Treg deletion, we treated Foxp3-GFP-DTR mice with 50, 10, 5 or 1 μg DTx per kg body weight and determined Foxp3+ Treg deletion after 24 h. A more than 90%downregulation of Foxp3+ Treg could be observed following the administration of 10 or 50 μg DTx per kg body weight (data not shown). Therefore we decided to use 10 μg DTx per kg body weight for our experiments.
Deletion of Treg leads to weight loss and death
Deletion of Treg induces inflammation in lung, liver, but hardly in the colon
Deletion of Treg activates CD4 + T cells
Deletion of Treg is the onset of chronic T cell-mediated intestinal inflammation
Deletion of Treg worsens acute intestinal inflammation
The immune system is pivotal in mediating the interactions between host and microbiota that shape the intestinal environment. Intestinal homeostasis arises from a highly dynamic balance between host protective immunity and regulatory mechanisms . This regulation is achieved by a number of cell populations acting through a set of shared regulatory pathways. Foxp3+ Treg play a nonredundant role in the maintenance of intestinal homeostasis through IL-10- and TGF-β1-dependent mechanisms [21, 22]. Their activity is complemented by other T and B lymphocytes. To allow for the induction and resolution of host protective immune responses, Treg development and activity is tightly linked to the inflammatory response. On the one hand, Treg control needs to be restrained to allow immune responses to proceed. On the other hand, Tregs have to keep pace with ongoing immune responses to restore the immune balance once inflammation is no longer required. Indeed, inflammation is often associated with increased numbers of Tregs. For instance, whereas the number of Foxp3+ Treg seems to be reduced in the peripheral blood of patients with IBD, the absolute Treg number seems to be increased in the mucosa of patients with IBD or celiac disease, probably as a consequence of the ongoing inflammation [23–29]. However, patients with mutations affecting the Foxp3 gene develop immune dysregulation, polyendocrinopathy, enteropathy, and X-linked syndrome (IPEX). IPEX is a fatal autoimmune disease starting early in life and affecting, among other organs, the skin and endocrine glands. However, the most frequently affected organ is the intestine, highlighting the importance of Tregs in maintaining intestinal tolerance . In the mouse, deficiency of the Foxp3 gene triggers a rapid fatal multi organ autoimmune disease [2, 3]. The time course of specific organ inflammation in the mouse seems to be altered in comparison to the human disease. Probably because of the rapid course of the pulmonary disease, these mice do not tend to develop intestinal inflammation, as they die due to a severe respiratory insufficiency.
Despite our limited understanding of the role of Foxp3+ Treg in the pathogenesis of human IBD, the ability to alter regulatory pathways may be a critical avenue for achieving long-term remission in patients. Results from animal models suggest that Foxp3+ Treg transfer in patients may be beneficial. However, most mouse models showing prevention or cure of colitis with Foxp3+ Treg have been conducted in lymphopenic animals, in which homeostatic expansion of Foxp3+ Treg may facilitate their impact on disease. Given that Foxp3+ Treg are already increased in number in the lamina propria of IBD patients, large numbers of transferred Foxp3+ Treg may be required to alter the balance between a regulatory and a proinflammatory response. In addition to the high number of Foxp3+ Treg necessary for cell therapeutic treatment, there is the risk that Foxp3+ Treg loose their suppressive capabilities in the course of time. Thus Foxp3+ Treg have been shown to be able to develop a proinflammatory phenotype by becoming exFoxp3 nonTreg which could presumably have deleterious effects in vivo [30, 31]. There is clearly a substantial need to gather more information about the role of Foxp3+ Treg for the intestinal homeostasis and the development of intestinal inflammation.
In order to determine the actual involvement of a reduction in Foxp3+ Treg for the development of an intestinal inflammation, we used the possibility to specifically delete Foxp3+ Treg in a genetically determined mouse model. The Foxp3-GFP-DTR mouse itself is immunocompentent and does not show any inflammatory phenotype per se [2, 3]. With this tool in hand, we could eliminate Foxp3+ Treg from a mouse with an initially intact intestinal homeostasis and barrier function initially. As expected, we could demonstrate that the elimination of Treg from mice with intact mucosal homeostasis led to the onset and aggravation of colitis.
The actual effect of Foxp3+ Treg deletion on the development of an intestinal inflammation is of utmost importance for the evaluation of therapeutic strategies in the treatment of human IBD, as medication is known to influence the distribution and function of Foxp3+ Treg. Saruta et al. have shown that the use of 6-mercatopurine and azathioprine, but not steroids or anti-TNF agents, was correlated with lower peripheral numbers of Treg . Moreover, in patients with rheumathoid arthritis, studies have demonstrated defective suppressor function of peripheral blood Treg that normalized following Infliximab therapy [33, 34]. A recent small study in children with Crohn´s disease showed increased Foxp3+ Treg in the colon of patients receiving Infliximab compared to those receiving other medications . Additionally, the probiotic VSL#3 increases the number of Foxp3+ Treg in the lamina propria of ileal pouches in patients with pouchitis . These studies suggest a potential role for Treg modulation in anti-TNF and probiotic therapy.
One major unanswered question is why inflammation persists in patients with active IBD despite high numbers of Foxp3+ Treg. Certainly, it is possible that in states of inflammation, when Foxp3+ Treg are recruited to or generated in the intestinal mucosa, there is a relative deficiency of these cells resulting in incomplete control of inflammation. However, it is also likely that both in vitro assays and murine models underestimate complexities in the regulation of the human intestinal milieu. In this environment, diverse responses to cytokines or costimulatory interactions may modify Foxp3+ Treg suppressive capabilities. To this end, IL-23, an inflammatory cytokine implicated in the pathogenesis of IBD in mice and humans, has recently been shown to inhibit the generation of Foxp3+ Treg in the colon [37–42]. Additionally, both murine and human Treg express toll-like receptors (TLR) and are therefore subject to regulation by pathogens that may alter their in vivo function. TLR signalling can result in either augmented (TLR 4 and TLR5) or abrogated (TLR8 and TLR9) Foxp3+ Treg-mediated suppressor function depending on the ligand engaged .
Intermittent depletion of Foxp3+ Treg aggravates intestinal inflammatory responses demonstrating the importance of Foxp3+ Treg for the balance at the mucosal surface of the intestine. From the literature and the data presented in this manuscript, one can conclude that Foxp3+ Treg inherit an important role for the establishment if intestinal homeostasis and for the control of intestinal inflammation. Future cell therapeutic strategies using Foxp3+ Treg seem to be a promising treatment option for patients with IBD. However, until then the complex interplay between Foxp3+ Treg and mucosal immunity needs to be further elucidated in order to prevent unexpected negative effects of this strategy.
This project was supported by the grant Fi1526/5-1 from the Deutsche Forschungsgemeinschaft. The authors gratefully acknowledge this support.
- Josefowicz SZ, Rudensky A: Control of regulatory T cell lineage commitment and maintenance. Immunity. 2009, 30: 616-625. 10.1016/j.immuni.2009.04.009.PubMed CentralView ArticlePubMed
- Kim JM, Rasmussen JP, Rudensky AY: Regulatory T cells prevent catastrophic autoimmunity throughout the lifespan of mice. Nat Immunol. 2007, 8: 191-197. 10.1038/ni1428.View ArticlePubMed
- Kim J, Lahl K, Hori S, Loddenkemper C, Chaudhry A, deRoos P, Rudensky A, Sparwasser T: Cutting edge: depletion of Foxp3+ cells leads to induction of autoimmunity by specific ablation of regulatory T cells in genetically targeted mice. J Immunol. 2009, 183: 7631-7634. 10.4049/jimmunol.0804308.View ArticlePubMed
- Fontenot JD, Gavin MA, Rudensky AY: Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol. 2003, 4: 330-336.View ArticlePubMed
- Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003, 299: 1057-1061. 10.1126/science.1079490.View ArticlePubMed
- Khattri R, Cox T, Yasayko SA, Ramsdell F: An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat Immunol. 2003, 4: 337-342.View ArticlePubMed
- Fontenot JD, Rasmussen JP, Williams LM, dooley JL, Farr AG, Rudensky AY: Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005, 22: 329-341. 10.1016/j.immuni.2005.01.016.View ArticlePubMed
- Brunkow ME, Jeffery EW, Hjerrild KA, Paeper B, Clark LB, Yasayko SA, Wilkinson JE, Galas D, Ziegler SF, Ramsdell F: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat Genet. 2001, 27: 68-73.View ArticlePubMed
- Wildin RS, Smyk-Pearson S, Filipovich AH: Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet. 2002, 39: 537-545. 10.1136/jmg.39.8.537.PubMed CentralView ArticlePubMed
- Shevach EM: Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity. 2009, 30: 636-645. 10.1016/j.immuni.2009.04.010.View ArticlePubMed
- Bouma G, Strober W: The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003, 3: 521-533. 10.1038/nri1132.View ArticlePubMed
- Izcue A, Coombes JL, Powrie F: Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation. Immunol Rev. 2006, 212: 256-271. 10.1111/j.0105-2896.2006.00423.x.View ArticlePubMed
- Izcue A, Coombes JL, Powrie F: Regulatory lymphocytes and intestinal inflammation. Annu Rev Immunol. 2009, 27: 313-338. 10.1146/annurev.immunol.021908.132657.View ArticlePubMed
- Izcue A, Powrie F: Special regulatory T-cell review: Regulatory T cells and the intestinal tract–patrolling the frontier. Immunology. 2008, 123: 6-10. 10.1111/j.1365-2567.2007.02778.x.PubMed CentralView ArticlePubMed
- Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F: Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005, 204: 184-194. 10.1111/j.0105-2896.2005.00250.x.View ArticlePubMed
- Fuss IJ, Marth T, Neurath MF, Pearlstein GR, Jain A, Strober W: Anti-interleukin 12 treatment regulates apoptosis of Th1 T cells in experimental colitis in mice. Gastroenterology. 1999, 117: 1078-1088. 10.1016/S0016-5085(99)70392-6.View ArticlePubMed
- Powrie F, Read S, Mottet C, Uhlig H, Maloy K: Control of immune pathology by regulatory T cells. Novartis Found Symp. 2003, 252: 92-98. discussion 98–105, 106–14View ArticlePubMed
- Read S, Powrie F: Induction of inflammatory bowel disease in immunodeficient mice by depletion of regulatory T cells. Curr Protoc Immunol. 2001,:Chapter 15:Unit 15 13
- Singh B, Read S, Asseman C, Malmstrom V, Mottet C, Stephens LA, Stepankova R, Tlaskalova H, Powrie F: Control of intestinal inflammation by regulatory T cells. Immunol Rev. 2001, 182: 190-200. 10.1034/j.1600-065X.2001.1820115.x.View ArticlePubMed
- Artis D: Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol. 2008, 8: 411-420. 10.1038/nri2316.View ArticlePubMed
- Barnes MJ, Powrie F: Regulatory T cells reinforce intestinal homeostasis. Immunity. 2009, 31: 401-411. 10.1016/j.immuni.2009.08.011.View ArticlePubMed
- Boden EK, Snapper SB: Regulatory T cells in inflammatory bowel disease. Curr Opin Gastroenterol. 2008, 24: 733-741. 10.1097/MOG.0b013e328311f26e.View ArticlePubMed
- Uhlig HH, Coombes J, Mottet C, Izcue A, Thompson C, Fanger A, Tannapfel A, Fontenot JD, Ramsdell F, Powrie F: Characterization of Foxp3+CD4+CD25+ and IL-10-secreting CD4+CD25+ T cells during cure of colitis. J Immunol. 2006, 177: 5852-5860.View ArticlePubMed
- Maul J, Loddenkemper C, Mundt P, Berg E, Giese T, Stallmach A, Zeitz M, Duchmann R: Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease. Gastroenterology. 2005, 128: 1868-1878. 10.1053/j.gastro.2005.03.043.View ArticlePubMed
- Holmen N, Lundgren A, Lundin S, Bergin AM, Rudin A, Sjovall H, Ohman L: Functional CD4+CD25 high regulatory T cells are enriched in the colonic mucosa of patients with active ulcerative colitis and increase with disease activity. Inflamm Bowel Dis. 2006, 12: 447-456. 10.1097/00054725-200606000-00003.View ArticlePubMed
- Eastaff-Leung N, Mabarrack N, Barbour A, Cummins A, Barry S: Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clin Immunol. 2010, 30: 80-89. 10.1007/s10875-009-9345-1.View ArticlePubMed
- Makita S, Kanai T, Oshima S, Uraushihara K, Totsuka T, Sawada T, Nakamura T, Koganei K, Fukushima T, Watanabe M: CD4+CD25bright T cells in human intestinal lamina propria as regulatory cells. J Immunol. 2004, 173: 3119-3130.View ArticlePubMed
- Sitohy B, Hammarstrom S, Danielsson A, Hammarstrom ML: Basal lymphoid aggregates in ulcerative colitis colon: a site for regulatory T cell action. Clin Exp Immunol. 2008, 151: 326-333. 10.1111/j.1365-2249.2007.03566.x.PubMed CentralView ArticlePubMed
- Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, Papadakis KA: Expression and functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm Bowel Dis. 2007, 13: 191-199. 10.1002/ibd.20053.View ArticlePubMed
- Zhou X, Bailey-Bucktrout S, Jeker LT, Bluestone JA: Plasticity of CD4(+) FoxP3(+) T cells. Curr Opin Immunol. 2009, 21: 281-285. 10.1016/j.coi.2009.05.007.PubMed CentralView ArticlePubMed
- Zhou X, Bailey-Bucktrout SL, Jeker LT, Penaranda C, Martinez-Llordella M, Ashby M, Nakayama M, Rosenthal W, Bluestone JA: Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol. 2009, 10: 1000-1007. 10.1038/ni.1774.PubMed CentralView ArticlePubMed
- Saruta M, Yu QT, Fleshner PR, Mantel PY, Schmidt-Weber CB, Banham AH, Papadakis KA: Characterization of FOXP3+CD4+ regulatory T cells in Crohn's disease. Clin Immunol. 2007, 125: 281-290. 10.1016/j.clim.2007.08.003.View ArticlePubMed
- Valencia X, Stephens G, Goldbach-Mansky R, Wilson M, Shevach EM, Lipsky PE: TNF down modulates the function of human CD4+CD25hi T-regulatory cells. Blood. 2006, 108: 253-261. 10.1182/blood-2005-11-4567.PubMed CentralView ArticlePubMed
- Nadkarni S, Mauri C, Ehrenstein MR: Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med. 2007, 204: 33-39. 10.1084/jem.20061531.PubMed CentralView ArticlePubMed
- Ricciardelli I, Lindley KJ, Londei M, Quaratino S: Anti tumour necrosis-alpha therapy increases the number of FOXP3 regulatory T cells in children affected by Crohn's disease. Immunology. 2008, 125: 178-183. 10.1111/j.1365-2567.2008.02839.x.PubMed CentralView ArticlePubMed
- Pronio A, Montesani C, Butteroni C, Vecchione S, Mumolo G, Vestri A, Vitolo D, Boirivant M: Probiotic administration in patients with ileal pouch-anal anastomosis for ulcerative colitis is associated with expansion of mucosal regulatory cells. Inflamm Bowel Dis. 2008, 14: 662-668. 10.1002/ibd.20369.View ArticlePubMed
- Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, Steinhart AH, Abraham C, Regueiro M, Griffiths A, Dassopoulos T, Bitton A, Yang H, Targan S, Datta LW, Kistner EO, Schumm LP, Lee AT, Gregersen PK, Barmada MM, Rotter JI, Nicolaed L, Cho JH: A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006, 314: 1461-1463. 10.1126/science.1135245.PubMed CentralView ArticlePubMed
- Hue S, Ahern P, Buonocore S, Kullberg MC, Cuad J, McKenzie BS, Powrie F, Maloy KJ: Interleukin-23drives innate and T cell-mediated intestinal inflammation. J Exp Med. 2006, 203: 2473-2483. 10.1084/jem.20061099.PubMed CentralView ArticlePubMed
- Elson CO, Cong Y, Weaver CT, Schoeb TR, McClanahan TK, Fick RB, Kastelein RA: Monoclonal anti-interleukin 23 reverses active colitis in a T cell-mediated model in mice. Gastroenterology. 2007, 132: 2359-2370. 10.1053/j.gastro.2007.03.104.View ArticlePubMed
- Kullberg MC, Jankovic D, Feng CG, Hue S, Gorelick PL, McKenzie BS, Cuad J, Powrie F, Cheever AW, Maloy KJ, Sher A: IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis. J Exp Med. 2006, 203: 2485-2494. 10.1084/jem.20061082.PubMed CentralView ArticlePubMed
- Uhlig HH, McKenzie BS, Hue S, Thompson C, Joyce-Shaikh B, Stepankova R, Robinson N, Buonocore S, Tlaskalova-Hogenova H, Cuad J, Powrie F: Differential activity of IL-12 and IL-23 in mucosal and systemic innate immune pathology. Immunity. 2006, 25: 309-318. 10.1016/j.immuni.2006.05.017.View ArticlePubMed
- Izcue A, Hue S, Buonocore S, Arancibia-Carcamo CV, Ahern PP, Iwakura Y, Maloy KJ, Powrie F: Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis. Immunity. 2008, 28: 559-570. 10.1016/j.immuni.2008.02.019.PubMed CentralView ArticlePubMed
- Liu G, Zhao Y: Toll-like receptors and immune regulation: their direct and indirect modulation on regulatory CD4+ CD25+ T cells. Immunology. 2007, 122: 149-156. 10.1111/j.1365-2567.2007.02651.x.PubMed CentralView ArticlePubMed
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-230X/12/97/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.